As per the research report, the size of the Europe Contrast Media Market is valued at USD 1.41 Billion in 2019 and estimated to grow at a CAGR of 5.2%, to reach USD 1.82 billion by 2024 during the forecast period 2019-2024. The Europe Contrast Media market is growing at a slow rate.
Contrast medium is a substance utilized as a part of medicinal imaging to upgrade the contrast of liquids or structures inside the body. This assistance in better imaging of anatomical structures and organs by expanding the picture contrast. Thus, these are useful in indicative strategies, for example, CT examines and in some basic surgeries. The worldwide contrast media or contrast specialist market is a genuinely develop and is required to witness solid development driven by expanding imaging conclusion and surgical systems.
Development of the contrast media or contrast operator market is driven by expanding interest for picture guided diagnostics and strategies, rising mortality of constant ailments, for example, malignancy, gastrointestinal scatters, and heart illnesses, and developing an interest for picture guided surgical methods. Development of the market can likewise be credited to variables, for example, expanding endorsements for contrast operators and rising number of private and government demonstrative communities for enhancing analytic imaging administrations. Besides, expanding research learns about uses of different contrast operators and solid pipeline results of the organizations are anticipated to make new open doors in the worldwide contrast media or specialist market.
This research report segmented and sub-segmented into the following categories:
The Europe had low CAGR during the forecast period. The reasons for the same might be the government policies.
Key players operating in the Europe Contrast Media Market profiled in this report are
CMC Contrast AB (Sweden), Daiichi Sankyo (Japan), Bayer HealthCare (Germany), GE Healthcare (U.S.), Guerbet Group (France), Bracco Imaging S.p.A. (Italy) in 2015. Lantheus Medical Imaging (U.S.), nanoPET Pharma GmbH (Germany), and Subhra Pharma Private Limited (India).are the leaders in the Europe Contrast Media market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Medical Procedure
5.1.1 Introduction
5.1.2 X-Ray/CT
5.1.3 MRI
5.1.4 Ultrasound
5.1.5 Y-o-Y Growth Analysis, By Medical Procedure
5.1.6 Market Attractiveness Analysis, By Medical Procedure
5.1.7 Market Share Analysis, By Medical Procedure
5.2 Route of Administration
5.2.1 Introduction
5.2.2 Injectable Contrasts Media
5.2.3 Oral Contrasts Media
5.2.4 Rectal Contrasts Media
5.2.5 Urethral Contrasts Media
5.2.6 Y-o-Y Growth Analysis, By Route of Administration
5.2.7 Market Attractiveness Analysis, By Route of Administration
5.2.8 Market Share Analysis, By Route of Administration
5.3 Type
5.3.1 Introduction
5.3.2 Iodinated Contrasts Media
5.3.3 Gadolinium-Based Contrasts Media
5.3.4 Microbubble Contrasts Media
5.3.5 Barium- Based Contrasts Media
5.3.6 Y-o-Y Growth Analysis, By Type
5.3.7 Market Attractiveness Analysis, By Type
5.3.8 Market Share Analysis, By Type
5.4 Indications
5.4.1 Introduction
5.4.2 Cardiovascular Disorders
5.4.3 Oncology
5.4.4 Neurological Disorders
5.4.5 Gastrointestinal Disorders
5.4.6 Nephrological Disorders
5.4.7 Musculoskeletal Disorders
5.4.8 Y-o-Y Growth Analysis, By Indications
5.4.9 Market Attractiveness Analysis, By Indications
5.4.10 Market Share Analysis, By Indications
5.5 Application
5.5.1 Introduction
5.5.2 Radiology
5.5.3 Interventional Cardiology
5.5.4 Interventional Radiology
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Medical Procedure
6.1.3.3 By Route of Administration
6.1.3.4 By Type
6.1.3.5 By Indication
6.1.3.6 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Medical Procedure
6.1.4.3 By Route of Administration
6.1.4.4 By Type
6.1.4.5 By Indication
6.1.4.6 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Medical Procedure
6.1.5.3 By Route of Administration
6.1.5.4 By Type
6.1.5.5 By Indication
6.1.5.6 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Medical Procedure Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Spago Nanomedical AB
8.3 Subhra Pharma Private Limited
8.4 Daiichi Sankyo
8.5 CMC Contrast AB
8.6 Nanopet Pharma GmbH
8.7 Guerbet Group
8.8 Bracco Imaging S.P.A
8.9 Bayer AG
8.10 Lantheus Medical Imaging (Subsidiary of Lantheus Holdings, Inc.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
